A Phase 2 Global Study conducted to see the benefit and safety of CC-486 alone and in combination with Durvalumab (MEDI4736) in patients with Myelodysplastic Syndromes who Did Not Respond to Treatment With Azacitidine for injection or Decitabine. : A Phase 2, International, Multicenter, Randomized, Open-label, Parallel Group Study to Evaluate the Efficacy and Safety of CC-486 (oral azacitidine) Alone and in Combination with Durvalumab (MEDI4736) in Subjects With Myelodysplastic Syndromes Who Fail to Achieve an Objective Response to Treatment With Azacitidine for Injection or Decitabine
Medienart: |
Klinische Studie |
---|
Erscheinungsjahr: |
2023 |
---|---|
Erschienen: |
2023 |
Enthalten in: |
WHO International Clinical Trials Registry Platform - (2023) vom: 21. Juni Zur Gesamtaufnahme - year:2023 |
---|
Sprache: |
Englisch |
---|
Links: |
Volltext [kostenfrei] |
---|
Anmerkungen: |
WHO International Clinical Trials Registry Platform (https://www.who.int/ictrp/en/), First posted: 30-03-2016, Last updated: 2023-06-29 |
---|
ICTRP ID: |
EUCTR2014-002675-29-DE |
---|
Förderinstitution / Projekttitel: |
|
---|
PPN (Katalog-ID): |
CTG004281829 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | CTG004281829 | ||
003 | DE-627 | ||
005 | 20230629100623.0 | ||
007 | cr uuu---uuuuu | ||
008 | 210507s2023 xx |||||o 00| ||eng c | ||
035 | |a (DE-627)CTG004281829 | ||
035 | |a (UBBS_Klinische_Studien_WHO)EUCTR2014-002675-29-DE | ||
035 | |a (UBBS_Klinische_Studien_WHO)CC-486-MDS-006 | ||
035 | |a (UBBS_Klinische_Studien_WHO)NCT02281084 | ||
035 | |a (UBBS_Klinische_Studien_WHO)2014-002675-29-FR | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
245 | 1 | 0 | |a A Phase 2 Global Study conducted to see the benefit and safety of CC-486 alone and in combination with Durvalumab (MEDI4736) in patients with Myelodysplastic Syndromes who Did Not Respond to Treatment With Azacitidine for injection or Decitabine. |b A Phase 2, International, Multicenter, Randomized, Open-label, Parallel Group Study to Evaluate the Efficacy and Safety of CC-486 (oral azacitidine) Alone and in Combination with Durvalumab (MEDI4736) in Subjects With Myelodysplastic Syndromes Who Fail to Achieve an Objective Response to Treatment With Azacitidine for Injection or Decitabine |
264 | 1 | |c 2023 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
500 | |a WHO International Clinical Trials Registry Platform (https://www.who.int/ictrp/en/), First posted: 30-03-2016, Last updated: 2023-06-29 | ||
650 | 4 | |a Medical Condition: Myelodysplastic syndrome (MDS) MedDRA version: 20.0Level: LLTClassification code 10068361Term: MDSSystem Organ Class: 100000004864;Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15] | |
650 | 4 | |a Study Type: Interventional | |
650 | 4 | |a Phase: Phase 2 | |
650 | 4 | |a Recruitment Status: Not yet recruiting | |
650 | 4 | |a 610 | |
773 | 0 | 8 | |i Enthalten in |t WHO International Clinical Trials Registry Platform |g (2023) vom: 21. Juni |
773 | 1 | 8 | |g year:2023 |g day:21 |g month:06 |
856 | 4 | 0 | |u https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2014-002675-29 |z kostenfrei |3 Volltext |
912 | |a GBV_CTG | ||
951 | |a AR | ||
952 | |j 2023 |b 21 |c 06 |